Suppr超能文献

剂量对人双氯芬酸葡萄糖醛酸化和硫酸化动力学的影响:单剂量研究

Effect of dose on the glucuronidation and sulphation kinetics of diflunisal in man: single dose studies.

作者信息

Loewen G R, Herman R J, Ross S G, Verbeeck R K

机构信息

College of Pharmacy, University of Saskatchewan, Saskatoon, Canada.

出版信息

Br J Clin Pharmacol. 1988 Jul;26(1):31-9. doi: 10.1111/j.1365-2125.1988.tb03360.x.

Abstract
  1. The effect of dose (100 mg, 250 mg, 500 mg, 750 mg and 1000 mg) on the glucuronidation and sulphation of diflunisal was studied in six healthy volunteers. 2. Total urinary recovery ranged from 78.9 +/- 11.9% to 91.5 +/- 18.7% of the administered dose. Urinary recovery (normalized for total urinary recovery) of diflunisal sulphate (DS) significantly increased with dose from 9.3 +/- 3.7% to 18.1 +/- 4.8%. 3. Normalized urinary recovery for diflunisal phenolic glucuronide (DPG) was unaffected by dose (range: 30.6 +/- 3.8% to 40.6 +/- 6.6%). Normalized urinary recovery for the acyl glucuronide (DAG) significantly decreased from 52.3 +/- 4.6% to 40.2 +/- 3.4% as the dose increased. 4. Total plasma clearance of diflunisal significantly decreased from 14.4 +/- 1.4 ml min-1 to 8.7 +/- 1.4 ml min-1 as the dose increased from 100 mg to 750 mg. A further increase in dose to 1000 mg resulted in an unexplained increase in total plasma clearance to 10.3 +/- 1.8 ml min-1. 5. Dose-dependent plasma clearance of diflunisal was caused mainly by saturation of the formation of DAG, whereas the formation of DS and DPG were relatively unaffected by dose.
摘要
  1. 在六名健康志愿者中研究了剂量(100毫克、250毫克、500毫克、750毫克和1000毫克)对双氯芬酸葡萄糖醛酸化和硫酸化的影响。2. 尿中总回收率为给药剂量的78.9±11.9%至91.5±18.7%。硫酸双氯芬酸(DS)的尿回收率(以尿总回收率标准化)随剂量从9.3±3.7%显著增加至18.1±4.8%。3. 双氯芬酸酚性葡萄糖醛酸苷(DPG)的标准化尿回收率不受剂量影响(范围:30.6±3.8%至40.6±6.6%)。随着剂量增加,酰基葡萄糖醛酸苷(DAG)的标准化尿回收率从52.3±4.6%显著降至40.2±3.4%。4. 随着剂量从100毫克增加到750毫克,双氯芬酸的总血浆清除率从14.4±1.4毫升/分钟显著降至8.7±1.4毫升/分钟。剂量进一步增加至1000毫克导致总血浆清除率出现无法解释的增加,达到10.3±1.8毫升/分钟。5. 双氯芬酸的剂量依赖性血浆清除率主要是由DAG形成的饱和引起的,而DS和DPG的形成相对不受剂量影响。

相似文献

9
Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis.
Eur J Clin Pharmacol. 1992;42(5):471-4. doi: 10.1007/BF00314852.

引用本文的文献

6
Diflunisal and its conjugates in patients with renal failure.双氟尼酸及其结合物在肾衰竭患者中的情况。
Br J Clin Pharmacol. 1991 May;31(5):546-50. doi: 10.1111/j.1365-2125.1991.tb05578.x.
7
Both phenolic and acyl glucuronidation pathways of diflunisal are impaired in liver cirrhosis.
Eur J Clin Pharmacol. 1992;42(5):471-4. doi: 10.1007/BF00314852.
8
Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors.
Clin Pharmacokinet. 1992 Oct;23(4):292-310. doi: 10.2165/00003088-199223040-00005.

本文引用的文献

2
Plasma protein binding and interaction studies with diflunisal, a new salicylate analgesic.
Biochem Pharmacol. 1980 Feb 15;29(4):571-6. doi: 10.1016/0006-2952(80)90378-0.
3
Drug metabolite kinetics.药物代谢动力学。
Pharmacol Ther. 1981;15(3):521-52. doi: 10.1016/0163-7258(81)90056-5.
5
Diflunisal disposition and hypouricemic response in osteoarthritis.
Clin Pharmacol Ther. 1983 Jun;33(6):813-21. doi: 10.1038/clpt.1983.111.
6
Pharmacokinetic consequences and toxicologic implications of endogenous cosubstrate depletion.
Drug Metab Rev. 1982;13(6):1009-20. doi: 10.3109/03602538208991374.
10
Review of the animal and clinical pharmacology of diflunisal.
Pharmacotherapy. 1983 Mar-Apr;3(2 Pt 2):9S-22S.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验